Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | ITPR3 | Q14573 | 7/20 | 0.48 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.48 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.48 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.47 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191662 | 1.00 | SMPD1 (0.50) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL7798872 | 1.00 | SMPD1 (0.50) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL30412792 | 0.94 | ITPR3 (0.52) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL8859419 | 0.94 | ITPR3 (0.52) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL30237668 | 0.91 | SMPD1 (0.54) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL170623 | 0.88 | SMPD1 (0.42) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL10611344 | 0.88 | SMPD1 (0.42) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL10611354 | 0.88 | SMPD1 (0.42) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL5378658 | 0.87 | SMPD1 (0.48) | SMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL4596697 | 0.87 | SMPD1 (0.48) | SMPD1ITPR3ITPR2ITPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464756-B1 | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof | DARM JERRY (US) | 2022-10-11 | — | — | US | disclosed |
| US-9610297-B2 | Stabilization of vitamin B12 | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-04-04 | — | — | US | disclosed |
| US-20160102313-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150328318-A1 | Stabilization of Vitamin B12 | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| EP-2121024-B1 | STABILIZATION OF VITAMIN B12 | BAYER IP GMBH (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-9089582-B2 | Stabilization of vitamin B12 | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20110065665-A1 | STABILIZATION OF VITAMIN B12 | BAYER ANIMAL HEALTH GMBH (DE) | 2011-03-17 | — | — | US | disclosed |
| CN-101631564-A | Vitamin B12Stabilization of | BAYER ANIMAL HEALTH GMBH | 2010-01-20 | — | — | CN | disclosed |
| EP-2121024-A2 | STABILIZATION OF VITAMIN B12 | Bayer Animal Health GmbH (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080261914-A1 | STABILIZATION OF VITAMIN B12 | BAYER HEALTHCARE AG (DE) | 2008-10-23 | — | — | US | disclosed |
| WO-2008113483-A2 | STABILIZATION OF VITAMIN B12 | BAYER ANIMAL HEALTH GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1161685-B1 | METHOD FOR REDUCING FLUORESCENCE QUENCHING IN BIOASSAYS | CIS BIO INT (FR) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328318-A1 | Stabilization of Vitamin B12 | HMBS, PROC, GC | SMPD1 4304/4885ITPR3 3221/4885ITPR2 3028/4885 |
| US-20110065665-A1 | STABILIZATION OF VITAMIN B12 | HMBS, PROC, GC | SMPD1 4304/4885ITPR3 3221/4885ITPR2 3028/4885 |
| US-20080261914-A1 | STABILIZATION OF VITAMIN B12 | HMBS, PROC, GC | SMPD1 4304/4885ITPR3 3221/4885ITPR2 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.